Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v.

Inclusion Criteria: * CKD subjects with or without dialysis treatment * Age over 18 years * Subjects requiring i.v. ESA treatment * Subjects likely to remain on i.v. ESA treatment for 6 months * Provision of informed consent - Exclusion Criteria: * Systemic immunosuppressive medication or any other drugs known to adversely affect the hemoglobin level * Known primary lack of efficacy (LOE), unexplained loss of effect to a recombinant erythropoietin product * History of PRCA or aplastic anemia * History of anti-erythropoietin antibodies * Uncontrolled hypertension * Pregnant woman or nursing mother * Women of childbearing potential do not agree to maintain effective birth control during the study treatment period.